Name: Yvonne Kalley Franklin | DOB: 6/17/1979 | MRN: U4772842 | PCP: Leilani D Paras, MD | Legal Name: Yvonne Kalley Franklin

# UW ONCOPLEX SINGLE GENE

Collected on Jul 24, 2026 11:08 AM

## Results

**OncoPlex Single Gene Sequenced Gene**

Value
**SEE NOTES**

(NOTE)
PIK3CA,AKT1,PTEN

**OncoPlex Single Gene Result**

Value
**1) POSITIVE for an activating mutation in PIK3CA (p.C420R). 2) NEGATIVE for activating alterations in AKT1. 3) NEGATIVE for inactivating alterations in PTEN, see interpretation.**

## OncoPlex Single Gene Interpretation

Value

**(NOTE)**

1) The tested tumor sample is POSITIVE for an activating mutation in PIK3CA (p.Cys420Arg, NM_006218.4:c.1258T>C, VAF 27%, also known as p.C420R). Clinical data indicates breast carcinomas with PIK3CA activating mutations may respond to pathway specific inhibitors (Janku 2012). A combination of fulvestrant plus alpelisib is approved for use in a subset of patients with ER+ breast cancers with activating PIK3CA mutations (Andre 2019), and capivasertib, in combination with fulvestrant, is approved for us in ER+/HER2- breast cancers with PIK3CA, AKT1, or PTEN mutations (Turner 2023, Howell 2022, Jones 2020). It is not known if the tested neoplasm would be susceptible to therapies targeting the relevant pathways or if this patient would benefit from such a therapeutic approach.

2) The tested tumor sample is NEGATIVE for activating mutations, amplifications, and structural rearrangements in the tested regions of AKT1.

3) The tested tumor sample is also NEGAT
IVE for inactivating
mutations, copy alterations, and structural rearrangements in the tested regions of PTEN.

UW-OncoPlex analysis was limited to PIK3CA, PTEN and AKT1. No other currently actionable mutations were otherwise detected in these genes. Some mutations in these genes will not be detected by this assay and not all detected variants are reported.

References:

1. Janku F, et al. PI3K.AKT.mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012, 30:777. PMID 22271473
2. Andre F, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019, 380:1929-1940 PMID 31091374
3. Turner NC, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023, 388:2058-2070 PMID 37256976
4. Howell SJ, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen r
eceptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022, 23:851-864 PMID 35671774
5. Jones RH, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2020, 21:345-357 PMID 32035020

**OncoPlex Single Gene Clinical Information**

Value
**Right iliac crest: Metastatic carcinoma, SU26-28598, block A1, collected on 07-24-2026.**

**OncoPlex Single Gene Method**

Value
**SEE NOTES**

Sequences are aligned to the human genome reference (hg38). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology.

This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine and Pathology. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

**Oncoplex Single Gene Director**

Value
**Interpreted by: Dr. Colin C. Pritchard, M.D., Ph.D.**

Scan 1

Authorizing provider: Lynn Symonds
Collection date: Jul 24, 2026 11:08 AM
Specimens: Whole blood
Result date: Aug 13, 2026 3:39 PM
Result status: Final
Resulting lab:
UWMC MONTLAKE DEPT OF LAB MED
1959 NE PACIFIC STREET
MS 357110
SEATTLE WA 98195-0001
206-598-6131
Xiaoli Chen, MD (Lab director)

MyChart® licensed from Epic Systems Corporation© 1999 - 2026